ARRAKIS THERAPEUTICS
Live / Allowed — Published for opposition (as of 10 Mar 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 04 Mar 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99065751
- Mark type
- Stylized text
- Filed
- 04 Mar 2025
- Published for opposition
- 10 Mar 2026
- Attorney of record
- Jennifer Insley-Pruitt
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, namely, small-molecule drugs for the treatment of cancer, neuromuscular, neurodegenerative, hematological, immune and cardiovascular diseases
Owner
- Arrakis Therapeutics, Inc., Waltham, MA, US
- Arrakis Therapeutics, Inc., Waltham, MA, US
Prosecution history
- 10 Mar 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 10 Mar 2026 — PUBLISHED FOR OPPOSITION
- 04 Mar 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 11 Feb 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 11 Feb 2026 — EXAMINER'S AMENDMENT ENTERED
- 11 Feb 2026 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 11 Feb 2026 — EXAMINERS AMENDMENT E-MAILED
- 11 Feb 2026 — EXAMINERS AMENDMENT -WRITTEN
- 11 Feb 2026 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 11 Feb 2026 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 14 Nov 2025 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 14 Nov 2025 — FINAL REFUSAL E-MAILED
- 14 Nov 2025 — FINAL REFUSAL WRITTEN
- 14 Oct 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 08 Oct 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE